Amyotrophic Lateral Sclerosis Treatment Market Analysis & Forecast: 2026-2033

Amyotrophic Lateral Sclerosis Treatment Market Size and Forecast – 2026 to 2033

The Amyotrophic Lateral Sclerosis Treatment Market is anticipated to grow at a CAGR of 6.1% with USD 789.4 Mn share in 2026 and is expected to reach USD 1,098.6 Mn in 2033. The rising prevalence of ALS, growing awareness of neurodegenerative disorders, and increased research investments are driving the growth of the amyotrophic lateral sclerosis treatment market. According to Target ALS, ALS is diagnosed annually in approximately 1.7–2.2 people per 100,000 population.

Key Takeaways

• Riluzole holds the largest market share of 53.3% in 2026 owing to the established first-line ALS therapy status. Riluzole was the first disease-modifying therapy approved for ALS, with randomized clinical trials demonstrating a significant survival benefit.
• Hospital Pharmacies expected to hold largest market share of 56.6% in 2026 owing to its requirement for medication monitoring and safety management.
• North America is expected to acquire the dominant share of 42.7% in 2026 owing to the favorable regulatory environment and orphan drug incentives. The U.S. Orphan Drug Act provides financial incentives to promote the development of treatments for rare diseases affecting fewer than 200,000 people in the United States.

Current Events and Their Impact on the Amyotrophic Lateral Sclerosis Treatment Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights 

To learn more about this report, Request Free Sample

Why is Riluzole Acquiring the Largest Market Share?

Riluzole holds the largest market share of 53.3% in 2026. Riluzole drives the Amyotrophic Lateral Sclerosis (ALS) treatment market through its proven clinical effectiveness, widespread physician adoption, and ability to help slow disease progression. Healthcare providers continue to rely on riluzole because ALS has limited treatment options and the number of diagnosed cases is increasing. Generic formulations enhance patient access, while its oral delivery method offers greater convenience. The continued combination of riluzole with emerging therapies further reinforces its importance in comprehensive ALS disease management. For instance, in February 2025, Biohaven Ltd. announced that the FDA accepted its NDA for troriluzole to treat adult spinocerebellar ataxia (SCA) patients and granted Priority Review.

Which Distribution Channel segment dominates the market? 

To learn more about this report, Request Free Sample

Hospital Pharmacies expected to hold largest market share of 56.6% in 2026. Hospital pharmacies support the Amyotrophic Lateral Sclerosis (ALS) treatment market by delivering specialized medications, managing therapies effectively, and facilitating coordinated patient care. The increasing demand for multidisciplinary ALS treatment, greater adoption of advanced therapies, and growing hospital-based patient care activities expand their role in disease management. Pharmacists monitor medication use, improve treatment adherence, and help optimize therapy outcomes. Strong supply capabilities and integration with specialty healthcare programs further strengthen the contribution of hospital pharmacies to ALS treatment.

Amyotrophic Lateral Sclerosis Treatment Market Trends

• Increasing adoption of established treatments such as riluzole and edaravone, along with emerging targeted therapies, supports disease progression management and improves patient care outcomes. Riluzole was the first FDA-approved disease-modifying therapy for ALS and has been shown to extend survival by approximately 2–3 months, while edaravone demonstrated efficacy in slowing functional decline in selected patients with early-stage ALS in clinical trials.
• Increasing availability of specialized ALS clinics and coordinated care programs involving neurologists, respiratory specialists, pharmacists, and rehabilitation teams improves comprehensive disease management worldwide. According to Target ALS, ALS is diagnosed annually in approximately 1.7–2.2 people per 100,000 population. In addition, the CDC estimates that nearly 30,000 people in the United States are living with ALS at any given time.

Regional Insights 

To learn more about this report, Request Free Sample

North America dominates owing to adoption of multidisciplinary ALS management approaches

North America is expected to acquire the dominant share of 42.70% in 2026. North America strengthens the Amyotrophic Lateral Sclerosis (ALS) treatment market by leveraging advanced healthcare infrastructure, extensive research capabilities, and rapid adoption of innovative therapies. The region supports ALS management through specialized clinics, greater disease awareness, improved diagnostic practices, and robust clinical trial activities. Favorable regulatory policies, access to advanced treatments, and established reimbursement systems improve patient availability of therapies. Pharmaceutical and biotechnology companies continue to invest in ALS research, accelerating the development and adoption of new treatment solutions across the region. In September 2025, Coya Therapeutics launched the Phase 2 ALSTARS trial to evaluate the safety and efficacy of COYA 302 in ALS patients.

Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Trends

Rising awareness of improved healthcare infrastructure, and increased investments in advanced therapies drive the Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market. Healthcare providers and researchers expand access to specialized facilities and develop innovative treatment solutions that support market growth. The growing elderly population and greater emphasis on early diagnosis and effective disease management further strengthen market expansion. Pharmaceutical companies and research organizations actively collaborate to accelerate the development of advanced ALS treatment options across the region. For instance, Biogen launched tofersen in China, introducing a gene-targeted ALS treatment aimed at slowing disease progression.

United States Amyotrophic Lateral Sclerosis Treatment Market Trends

The United States Amyotrophic Lateral Sclerosis (ALS) treatment market expands due to rising disease awareness, research advancements, innovative therapies, improved diagnostics, and increased clinical investments. Pharmaceutical companies, healthcare providers, and specialized ALS care centers support market growth by enhancing treatment accessibility and developing effective disease management solutions.

Japan Amyotrophic Lateral Sclerosis Treatment Market Trends

Japan’s Amyotrophic Lateral Sclerosis (ALS) treatment market grows through rising awareness of neurological disorders, better diagnostic capabilities, and demand for advanced therapies. Japan’s robust healthcare system, focus on medical research, and adoption of innovative treatments strengthen market development. Government support for rare disease management, expansion of specialized care facilities, and increased investment in drug research and clinical trials further improve ALS treatment access and patient outcomes.

Who are the Major Companies in Amyotrophic Lateral Sclerosis Treatment Industry

Some of the major key players in Amyotrophic Lateral Sclerosis Treatment Market are Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company Ltd., Sanofi S.A., and Mylan Pharmaceuticals Inc.

Key News

• In September 2025, I AM ALS and actor Eric Dane launched the Push for Progress campaign to accelerate ALS research, improve treatment access, and secure $1 billion in federal ALS funding over three years.

Market Report Scope

Analyst Opinion

• The ALS treatment market is primarily driven by an increasing unmet medical need rather than short-term healthcare trends. ALS remains a progressive and fatal neurodegenerative disorder, with approximately 120,000 people affected globally at any given time. The limited availability of disease-modifying therapies and the need for treatments that can extend survival and improve quality of life continue to create strong demand for innovative solutions.
• Therapeutic innovation will remain the key growth catalyst, as existing ALS treatments provide only modest benefits. For example, approved therapies such as riluzole and edaravone have demonstrated the ability to slow disease progression in selected patient groups, but they do not address the underlying causes of ALS. This treatment gap is accelerating investment in gene therapies, biomarker-driven approaches, and targeted drug development, particularly for genetically linked ALS cases involving mutations such as SOD1.
• Advances in precision medicine are expected to reshape ALS treatment strategies. Clinical breakthroughs, including the approval of Qalsody (tofersen) for SOD1 mutation-associated ALS, demonstrate the potential of genetic targeting in rare neurological diseases. With genetic mutations contributing to a subset of ALS cases, the shift toward personalized therapies is likely to encourage broader adoption of molecular diagnostics and specialized treatment pathways.

Market Segmentation

• By Drug Type (Revenue, USD Bn, 2021-2033)
  • Riluzole
  • Edaravone (Radicava)
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
  • Hospital Pharmacies
  • Retail & Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research interviews

• Neurologists, ALS specialists, and healthcare professionals involved in diagnosis and treatment of ALS patients
• Pharmaceutical and biotechnology industry professionals engaged in ALS drug development and clinical research
• Clinical trial investigators, researchers, and academic experts specializing in neurodegenerative diseases
• Hospital administrators and healthcare providers involved in neurological care
• Patient advocacy groups and ALS support organizations

Databases

• Clinical trial databases including ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP)
• U.S. Food and Drug Administration (FDA) databases for drug approvals, regulatory updates, and therapeutic development information
• European Medicines Agency (EMA) databases for medicines and regulatory assessments
• National Institutes of Health (NIH) and National Library of Medicine (NLM) databases
• PubMed and biomedical literature databases
• World Health Organization (WHO) health statistics and disease burden databases
• National health system databases and publicly available epidemiological repositories

Magazines

• Healthcare and biotechnology industry publications
• Pharmaceutical innovation and life sciences magazines
• Neurology and medical technology magazines
• Healthcare policy and disease awareness publications

Journals

• Peer-reviewed journals covering neurology, neuroscience, neurodegenerative disorders, and clinical medicine
• Publications focused on ALS pathophysiology, diagnosis, biomarkers, and treatment advancements
• Journals covering clinical trials, precision medicine, gene therapy, and drug development
• Medical research journals indexed in PubMed and other scientific databases

Newspapers

• Global healthcare and science news publications
• Business and biotechnology news sources covering pharmaceutical developments
• Publications reporting regulatory approvals, clinical trial outcomes, and healthcare innovations

Associations

• Amyotrophic Lateral Sclerosis Association
• International Alliance of ALS/MND Associations
• European Academy of Neurology
• American Academy of Neurology
• National neurological disease and patient advocacy organizations

Public Domain sources

• Government healthcare databases and regulatory authority publications
• National disease surveillance reports and epidemiological studies
• Publicly available clinical trial registries
• Government-funded research publications and healthcare statistics
• Open-access scientific publications and medical research repositories
• Public health reports from international health organizations

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 10 years